via Royal Melbourne Institute of Technology
RMIT scientists have created a new type of antibiotic that can be rapidly re-engineered to avoid resistance by dangerous superbugs.
Developed by PhD candidate Priscila Cardoso and principal supervisor Dr Céline Valéry from the School of Health and Biosciences, the antibiotic has a simple design that allows it to be produced quickly and cost-effectively in a lab.
Named Priscilicidin, the antibiotic’s amino acid building blocks are small, so it can be tailored to tackle different types of antimicrobial resistance.
With the World Health Organization calling antimicrobial resistance “one of the top ten global public health threats facing humanity”, developing new antibiotics is more urgent than ever.
Professor Charlotte Conn, one of Cardoso’s PhD supervisors, said given that urgency, Priscilicidin was an exciting breakthrough for public health.
Priscilicidin is a type of antimicrobial peptide. These peptides are produced by all living organisms as the first defense against bacteria and viruses.
After reviewing the literature on antimicrobial peptide molecular engineering, the team designed and tested 20 short peptides before settling on Priscilicidin as the best candidate.
“The pharmaceutical industry generally tests thousands of compounds before getting a lead candidate. In our case, only 20 designs were necessary to create an entire new family of antibiotics,” Valéry said.
Conn said Priscilicidin was based on a natural antibiotic peptide, which made it less likely to cause antimicrobial resistance compared to existing conventional antibiotics.
“Current natural antibiotics are expensive and difficult to make on a large scale. They also break down quickly in the body,” she said
“Priscilicidin combines the advantages of small molecular design, which means it’s quick and inexpensive to synthesise in a lab, with the advantages of natural antibiotics.”
How does Priscilicidin work?
Priscilicidin was derived from Indolicidin, a natural antibiotic found in cows’ immune systems.
The team’s research, published in January 2023 in the Women in Nanoscience 2022 special issue of Frontiers in Chemistry, showed Priscilicidin was highly active against resistant microbial strains such as golden staph, E. coli bacteria and candida fungi.
Priscilicidin works by disturbing the membrane of the microbes, eventually killing the cell.
“Attacking this outer layer makes it harder for the bacteria to evolve and resist treatment,” said Valéry.
Lab tests showed Priscilicidin had a similar antimicrobial activity as Indolicidin on common bacterial and fungal infections.
A new arsenal of topical and oral antibiotics
The team’s research shows Priscilicidin’s molecules naturally self-assemble into hydrogel form, making it ideal for creating antibiotic gels and creams.
Valéry said when new drugs were created, scientists needed to consider the drug’s pharmaceutical formulation.
This includes the drug’s form (capsule or cream, for example) and processes involved. Priscilicidin’s natural hydrogel form meant they can bypass some of that formulation process, Valéry said.
“The fact we can control the viscosity of Priscilicidin means we can contemplate many applications as different products, diversifying the types of treatments to stop antimicrobial resistance,” she said.
While the team are predominantly investigating Priscilicidin for topical applications, they are not ruling out oral applications.
“In theory, you could choose all means of administration for Priscilicidin, but none of them have been tested yet,” Conn said.
“We have an oral delivery technology at RMIT for protein and peptide drugs, which will allow antimicrobial peptides to be administered orally. We are currently looking at Priscilicidin as a candidate for this test.”
Original Article: Antibiotic innovation helps fight against superbugs
More from: Royal Melbourne Institute of Technology | Commonwealth Scientific and Industrial Research Organisation
The Latest Updates from Bing News
Go deeper with Bing News on:
Priscilicidin
- Feed has no items.
Go deeper with Bing News on:
Antimicrobial resistance
- Better medical record-keeping needed to fight antibiotic overuse
A lack of detailed record-keeping in clinics and emergency departments may be getting in the way of reducing the inappropriate use of antibiotics, a pair of new studies suggests. In one of the studies ...
- WHO warns of intensified antimicrobial resistance, updating priority pathogen list
The EU’s Health Emergency Preparedness and Response Authority (HERA) welcomes publication of the updated World Health Organisation Bacterial Priority Pathogens List (WHO BPPL).
- AI uncovers gaps in global antimicrobial resistance research
Artificial Intelligence (AI) has helped identify knowledge, methodological and communication gaps in global Antimicrobial Resistance (AMR) research. In a new study carried out by the Chinese Academy ...
- Global Antimicrobial Coated Medical Devices Market Set to Surge to USD 5,123.5 Million by 2033
Antimicrobial Coated Medical Devices Market is expected to rise to US$ 5,123.5 million by 2033, register a significant CAGR of 13.2%, ...
- Call for actionable steps in response to the rising threat of antimicrobial resistance (AMR)
Antimicrobial resistance (AMR) is one of the greatest global threats to public health and development. Limiting the emergence and spread of resistant pathogens is critical to treating diseases in ...